Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125547451 | 12554745 | 1 | I | 2016 | 20160707 | 20160713 | 20160713 | EXP | FR-009507513-1607FRA004210 | MERCK | 55.44 | YR | F | Y | 0.00000 | 20160713 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125547451 | 12554745 | 1 | PS | CUBICIN | DAPTOMYCIN | 1 | Intravenous (not otherwise specified) | 500 MG, QD | 6500 | MG | 21572 | 500 | MG | INJECTION | QD | ||||
| 125547451 | 12554745 | 2 | SS | OMEPRAZOLE MYLAN | OMEPRAZOLE | 1 | Intravenous (not otherwise specified) | 40 MG, QD | 0 | 40 | MG | POWDER FOR INJECTION | QD | ||||||
| 125547451 | 12554745 | 3 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 4.5 DF, TID | 526.5 | DF | 0 | 4.5 | DF | TID | |||||
| 125547451 | 12554745 | 4 | SS | BISOCOR | BISOPROLOL FUMARATE | 1 | Oral | 1.5 DF, QD | 18 | DF | 0 | 1.5 | DF | SCORED TABLET | QD | ||||
| 125547451 | 12554745 | 5 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | 5 ML, QD | 0 | 5 | ML | ORAL SOLUTION | QD | |||||||
| 125547451 | 12554745 | 6 | SS | INSULATARD (INSULIN, ISOPHANE) | INSULIN HUMAN | 1 | Subcutaneous | 8 IU, QD | 48 | IU | 0 | 8 | IU | QD | |||||
| 125547451 | 12554745 | 7 | SS | NOVORAPID | INSULIN ASPART | 1 | Subcutaneous | 0 | |||||||||||
| 125547451 | 12554745 | 8 | SS | PHLOROGLUCINOL (+) TRIMETHYLPHLOROGLUCINOL | PHLOROGLUCINOL1,3,5-TRIMETHOXYBENZENE | 1 | Intravenous (not otherwise specified) | 1 DF, QD | 0 | 1 | DF | SOLUTION FOR INJECTION | QD | ||||||
| 125547451 | 12554745 | 9 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QD | 23 | DF | 0 | 1 | DF | FILM-COATED TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125547451 | 12554745 | 1 | Bacterial infection |
| 125547451 | 12554745 | 2 | Oesophagitis |
| 125547451 | 12554745 | 3 | Pneumocystis jirovecii pneumonia |
| 125547451 | 12554745 | 5 | Acquired immunodeficiency syndrome |
| 125547451 | 12554745 | 6 | Type 2 diabetes mellitus |
| 125547451 | 12554745 | 7 | Type 2 diabetes mellitus |
| 125547451 | 12554745 | 8 | Acquired immunodeficiency syndrome |
| 125547451 | 12554745 | 9 | Acquired immunodeficiency syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125547451 | 12554745 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125547451 | 12554745 | Acute kidney injury | |
| 125547451 | 12554745 | Bacterial sepsis | |
| 125547451 | 12554745 | Fungal sepsis | |
| 125547451 | 12554745 | Haemodialysis | |
| 125547451 | 12554745 | Histiocytosis haematophagic | |
| 125547451 | 12554745 | Multiple organ dysfunction syndrome | |
| 125547451 | 12554745 | Pancytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125547451 | 12554745 | 1 | 20160512 | 20160528 | 0 | |
| 125547451 | 12554745 | 2 | 20160511 | 0 | ||
| 125547451 | 12554745 | 3 | 20160416 | 20160525 | 0 | |
| 125547451 | 12554745 | 4 | 20160513 | 20160524 | 0 | |
| 125547451 | 12554745 | 5 | 20160513 | 0 | ||
| 125547451 | 12554745 | 6 | 20160516 | 20160521 | 0 | |
| 125547451 | 12554745 | 8 | 20160511 | 0 | ||
| 125547451 | 12554745 | 9 | 20160430 | 20160522 | 0 |